Navigation Links
Pancreatic cancers use fructose, common in the Western diet, to fuel their growth
Date:8/3/2010

Pancreatic cancers use the sugar fructose, very common in the Western diet, to activate a key cellular pathway that drives cell division, helping the cancer to grow more quickly, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has found.

Although it's widely known that cancers use glucose, a simple sugar, to fuel their growth, this is the first time a link has been shown between fructose and cancer proliferation, said Dr. Anthony Heaney, an associate professor of medicine and neurosurgery, a Jonsson Cancer Center researcher and senior author of the study.

"The bottom line is the modern diet contains a lot of refined sugar including fructose and it's a hidden danger implicated in a lot of modern diseases, such as obesity, diabetes and fatty liver," said Heaney, who also serves as director of the Pituitary Tumor and Neuroendocrine Program at UCLA. "In this study, we show that cancers can use fructose just as readily as glucose to fuel their growth."

The study appeared in the Aug. 1 issue of the peer-reviewed journal Cancer Research.

The source of fructose in the Western diet is high fructose corn syrup (HFCS), a corn-based sweetener that has been on the market since about 1970. HFCS accounts for more than 40 percent of the caloric sweeteners added to foods and beverages, and it is the sole sweetener used in American soft drinks.

Between 1970 and 1990, the consumption of HFCS in the U.S. has increased over 1,000 percent, according to an article in the April 2004 issue of the American Journal of Clinical Nutrition. Food companies use HFCS - a mixture of fructose and glucose - because it's inexpensive, easy to transport and keeps foods moist. And because it is so sweet, it's cost effective for companies to use small quantities of HCFS in place of more expensive sweeteners or flavorings.

In his study, Heaney and his team took pancreatic tumors from patients and cultured and grew the malignant cells in Petri dishes. They then added glucose to one set of cells and fructose to another. Using mass spectrometry, they were able to follow the carbon-labeled sugars in the cells to determine what exactly they were being used for and how.

Heaney found that the pancreatic cancer cells could easily distinguish between glucose and fructose even though they are very similar structurally, and contrary to conventional wisdom, the cancer cells metabolized the sugars in very different ways. In the case of fructose, the pancreatic cancer cells used the sugar in the transketolase-driven non-oxidative pentose phosphate pathway to generate nucleic acids, the building blocks of RNA and DNA, which the cancer cells need to divide and proliferate.

"Traditionally, glucose and fructose have been considered as interchangeable monosaccharide substrates that are similarly metabolized, and little attention has been given to sugars other than glucose," the study states. "However, fructose intake has increased dramatically in recent decades and cellular uptake of glucose and fructose uses distinct transporters These findings show that cancer cells can readily metabolize fructose to increase proliferation. They have major significance for cancer patients, given dietary refined fructose consumption."

As in anti-smoking campaigns, a federal effort should be launched to reduce refined fructose intake, Heaney said.

"I think this paper has a lot of public health implications," Heaney said. "Hopefully, at the federal level there will be some effort to step back on the amount of HFCS in our diets."

Heaney said that while this study was done in pancreatic cancer, these finding may not be unique to that cancer type.

Going forward, Heaney and his team are exploring whether it's possible to block the uptake of fructose in the cancer cells with a small molecule, taking away one of the fuels they need to grow. The work is being done in cell lines and in mice, Heaney said.


'/>"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Related biology news :

1. TGen-Asuragen partner to advance pancreatic cancer research
2. Predicting prognosis and treatment response in a subset of pancreatic cancer patients
3. Soft drink consumption may increase risk of pancreatic cancer
4. Oral COTI-2 is effective in a second animal model of human pancreatic cancer
5. Pancreatic Cancer Action Network-AACR Pathway to Leadership Grant awarded to Johns Hopkins Early Career investigator
6. ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER
7. Blood-flow metabolism mismatch predicts pancreatic tumor aggressiveness
8. Newly discovered epidermal growth factor receptor active in human pancreatic cancers
9. Device protects transplanted pancreatic cells from the immune system
10. Compendium of pancreatic cancer biomarkers established as strategic approach to early-detection
11. HIV-1 protease inhibitor induced oxidative stress in pancreatic B-cells: thymoquinone protection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions America ... management products and solutions and a cutting-edge manufacturer ... that it is offering seamless, integrated solutions that ... entrance products. The solutions provide IdentyTech,s customers with ... their facilities from crime and theft. ...
(Date:12/15/2016)... BADEN-BADEN, Germany , December 15, 2016 /PRNewswire/ ... services provider, today announced an agreement with NuData Security, ... join forces. The partnership will enable clients to focus on ... with local data protection regulation. ... In order to provide a one-stop ...
(Date:12/15/2016)... Dec. 15, 2016 Advancements in ... health wellness and wellbeing (HWW), and security ... three new passenger vehicles begin to feature ... recognition, heart beat monitoring, brain wave monitoring, ... monitoring, and pulse detection. These will be ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... a global Phase 2b induction study in ulcerative ... alpha4beta7 integrin. The aim of this randomized, double-blind, ... safety/tolerability and efficacy of PTG-100 in approximately 240 ... active disease. "We are very ...
(Date:1/16/2017)... N.Y. , Jan. 16, 2017   Valentin ... J. Tracey, MD , president and CEO of ... Health, completed an analysis of how the nervous system ... identify and develop bioelectronic medicine devices to ... in Nature Neuroscience . The paper ...
(Date:1/14/2017)... Diego, CA (PRWEB) , ... January 14, 2017 ... ... of Proximo™, a new service providing complete end-to-end genome assemblies to researchers around ... complete genomes eliminates a major obstacle in answering a wide range of scientific ...
(Date:1/13/2017)... 13, 2017 Research and Markets has announced the ... offering. ... market to grow at a CAGR of 16.83% during the period 2017-2021. ... prospects of the global biopolymers market for 2017-2021. To calculate the market ... of biopolymer products. The report also includes a a discussion of the ...
Breaking Biology Technology: